Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

WINT

Windtree Therapeutics (WINT)

Windtree Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:WINT
DateTimeSourceHeadlineSymbolCompany
17/12/202400:00GlobeNewswire Inc.Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials ConferenceNASDAQ:WINTWindtree Therapeutics Inc
10/12/202400:00GlobeNewswire Inc.Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial ArrhythmiaNASDAQ:WINTWindtree Therapeutics Inc
05/12/202423:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
05/12/202400:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
05/12/202400:00GlobeNewswire Inc.Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic TransactionNASDAQ:WINTWindtree Therapeutics Inc
28/11/202408:43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
28/11/202408:05GlobeNewswire Inc.Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business UpdatesNASDAQ:WINTWindtree Therapeutics Inc
15/11/202400:53Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:WINTWindtree Therapeutics Inc
15/11/202400:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
15/11/202400:00GlobeNewswire Inc.Windtree Announces Leadership Transition Plan With Industry VeteransNASDAQ:WINTWindtree Therapeutics Inc
05/11/202400:00GlobeNewswire Inc.Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong KongNASDAQ:WINTWindtree Therapeutics Inc
30/10/202423:00GlobeNewswire Inc.Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3NASDAQ:WINTWindtree Therapeutics Inc
23/10/202423:00GlobeNewswire Inc.Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the WorldNASDAQ:WINTWindtree Therapeutics Inc
21/10/202423:00GlobeNewswire Inc.Windtree To Present at the ThinkEquity Conference on October 30thNASDAQ:WINTWindtree Therapeutics Inc
17/10/202423:15GlobeNewswire Inc.Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for JapanNASDAQ:WINTWindtree Therapeutics Inc
09/10/202423:00GlobeNewswire Inc.Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial DesignNASDAQ:WINTWindtree Therapeutics Inc
09/10/202422:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:WINTWindtree Therapeutics Inc
30/09/202422:15GlobeNewswire Inc.Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic ShockNASDAQ:WINTWindtree Therapeutics Inc
27/09/202406:05GlobeNewswire Inc.Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ETNASDAQ:WINTWindtree Therapeutics Inc
25/09/202422:15GlobeNewswire Inc.Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic ShockNASDAQ:WINTWindtree Therapeutics Inc
25/09/202422:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
25/09/202407:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:WINTWindtree Therapeutics Inc
04/09/202422:00GlobeNewswire Inc.Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic ShockNASDAQ:WINTWindtree Therapeutics Inc
04/09/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:WINTWindtree Therapeutics Inc
04/09/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:WINTWindtree Therapeutics Inc
03/09/202423:10Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:WINTWindtree Therapeutics Inc
03/09/202423:09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:WINTWindtree Therapeutics Inc
03/09/202421:26Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:WINTWindtree Therapeutics Inc
03/09/202421:22Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:WINTWindtree Therapeutics Inc
24/08/202406:15Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:WINTWindtree Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:WINT